B. Bandelow

发表

Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition

D. Nutt, N. Fineberg, S. Chamberlain, 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder

D. Wedekind, A. Broocks, B. Bandelow, 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia

E. Rüther, G. Hajak, B. Bandelow, 1995, European Psychiatry.

Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder

D. Wedekind, B. Bandelow, 2015, Human psychopharmacology.

[Pharmacotherapy of anxiety disorders-Guideline-conform treatment and new developments].

P. Zwanzger, B. Bandelow, N. Singewald, 2021, Der Nervenarzt.

Salivary, total plasma and plasma free cortisol in panic disorder

E. Rüther, G. Hajak, D. Wedekind, 2000, Journal of Neural Transmission.

Treatment of anxiety disorders

D. Wedekind, B. Bandelow, Sophie Michaelis, 2017, Dialogues in clinical neuroscience.

Epidemiology of anxiety disorders in the 21st century

B. Bandelow, Sophie Michaelis, Borwin Bandelow, 2015, Dialogues in clinical neuroscience.

Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls

Göran Hajak, E. Rüther, G. Hajak, 2005, Psychiatry Research.

The Medical Treatment of Obsessive-Compulsive Disorder and Anxiety

B. Bandelow, 2008, CNS Spectrums.

Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics

D. Nutt, N. Fineberg, K. Domschke, 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Paul McCrone, Hans-Ulrich Wittchen, Naomi Fineberg, 2014, Journal of psychopharmacology.

Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option?

W. Zieglgänsberger, C. Wotjak, B. Lutz, 2022, Medical Cannabis and Cannabinoids.

Panic disorder during pregnancy and postpartum period

E. Rüther, S. Bleich, G. Hajak, 2006, European Psychiatry.

Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder.

E. Rüther, G. Hajak, A. Broocks, 2002, Comprehensive psychiatry.

A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder

Dan J Stein, Leonardo Franklin Fontenelle, M. Stein, 2010, Current psychiatry reports.

Increased psychological responses and divergent neuroendocrine responses to m‐CPP and ipsapirone in patients with panic disorder

E. Rüther, G. Hajak, A. Broocks, 2000, International clinical psychopharmacology.

The diagnosis of and treatment recommendations for anxiety disorders.

M. Beutel, B. Bandelow, S. Rudolf, 2014, Deutsches Arzteblatt international.

Anxiety symptom severity and functional recovery or relapse.

Dan J Stein, D. Baldwin, O. Dolberg, 2009, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: A pilot study with the binocular depth inversion paradigm

H. Emrich, B. Bandelow, M. Borsutzky, 2013, Psychology, health & medicine.

What treatments do patients with panic disorder and agoraphobia get?

E. Rüther, G. Hajak, B. Bandelow, 2005, European Archives of Psychiatry and Clinical Neuroscience.

The best next drug in the course of generalized anxiety disorders: the “PN-GAD-algorithm”

H. Möller, H. Volz, S. Kasper, 2013, International journal of psychiatry in clinical practice.

An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder

S. Pallanti, D. Baldwin, C. Allgulander, 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

S. Kasper, B. Bandelow, B. Herman, 2009 .

P.3.004 The application of the panic and agoraphobia scale (PAS) in clinical trials

E. Rüther, A. Broocks, B. Bandelow, 1997, European Neuropsychopharmacology.

Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect?

P. Falkai, K. Domschke, D. Wedekind, 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Association analysis of Rgs7 variants with panic disorder

W. Maier, V. Arolt, K. Domschke, 2009, Journal of Neural Transmission.

Rgs 2 gene polymorphisms as modulators of anxiety in humans?

C. Freitag, R. Fimmers, J. Flint, 2006, Journal of Neural Transmission.

Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder

G. Hajak, A. Broocks, F. Hohagen, 2002, Neuropsychopharmacology.

Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder

E. Rüther, G. Hajak, D. Wedekind, 2004, European Archives of Psychiatry and Clinical Neuroscience.

The German Guidelines for the treatment of anxiety disorders: first revision

M. Beutel, B. Bandelow, S. Rudolf, 2021, European Archives of Psychiatry and Clinical Neuroscience.

WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults

E. Hollander, D. Nutt, J. Greist, 2003, CNS Spectrums.

Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients

J. Wiltfang, D. Wedekind, B. Bandelow, 2021, Human psychopharmacology.

Nocturnal Melatonin Secretion and Sleep after Doxepin Administration in Chronic Primary Insomnia

E. Rüther, G. Herrendorf, G. Hajak, 1996, Pharmacopsychiatry.

Non-pharmacological treatment

K. Domschke, D. Baldwin, B. Bandelow, 2013 .

Randomized double blind comparison of olanzapine vs. clozapine on subjective well‐being and clinical outcome in patients with schizophrenia

M. Lambert, D. Naber, M. Riedel, 2005, Acta psychiatrica Scandinavica.

Myocarditis Associated with Clozapine Treatment

E. Rüther, S. Bleich, B. Bandelow, 2000 .

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.

J. Bobes, B. Bandelow, G. Chouinard, 2010, The international journal of neuropsychopharmacology.

What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?

D. Stein, D. Baldwin, O. Dolberg, 2006, The Journal of clinical psychiatry.

Neuropeptide S Receptor (NPSR) Gene - Converging Evidence for a Role in Panic Disorder

A. Gloster, G. Alpers, W. Maier, 2020 .

Diurnal variation of cortisol in panic disorder

E. Rüther, D. Wedekind, A. Broocks, 2000, European Neuropsychopharmacology.

Zur sozialen Situation schizophrener Patienten

W. Gaebel, B. Bandelow, F. Müller-Spahn, 1998, Der Nervenarzt.

Generalized Anxiety Disorder and Pain.

B. Bandelow, 2015, Modern trends in pharmacopsychiatry.

Recommendations for the Long-Term Treatment of Anxiety Disorders

E. Hollander, M. Pollack, J. Greist, 2003 .

Aripiprazole , a “ Dopamine-Serotonin System Stabilizer ” in the Treatment of Psychosis

B. Bandelow, 2003 .

Cardio-respiratory and other symptom clusters in panic disorder.

O. Benkert, A. Nardi, I. Marks, 1996, Anxiety.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders

D. Rujescu, E. Hollander, N. Fineberg, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Polymorphism of the gene of angiotensin converting enzyme: lack of association with mood disorder

E. Rüther, J. Kornhuber, B. Bandelow, 2000, Journal of Neural Transmission.

Internet psychotherapeutic interventions for anxiety disorders – a critical evaluation

D. Wedekind, B. Bandelow, 2022, BMC Psychiatry.

The myth that psychotherapy is more effective than pharmacotherapy in anxiety disorders

B. Bandelow, 2021, European Neuropsychopharmacology.

Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects

E. Rüther, G. Hajak, B. Bandelow, 1996, European Neuropsychopharmacology.

Pharmacological treatment of panic disorder.

P. Zwanzger, D. Baldwin, B. Bandelow, 2013, Modern trends in pharmacopsychiatry.

Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo

Dan J Stein, D. Baldwin, O. Dolberg, 2007, Pharmacopsychiatry.

Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post‐marketing surveillance of 16 944 cases

G. Hajak, B. Bandelow, Göran Hajak, 1998, International clinical psychopharmacology.

Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine

W. Paulus, B. Bandelow, S. Link, 2009, Movement disorders : official journal of the Movement Disorder Society.

Salivary cortisol in panic attacks.

E. Rüther, G. Hajak, D. Wedekind, 2000, The American journal of psychiatry.

Urinary Excretion of Cortisol, Norepinephrine, Testosterone, and Melatonin in Panic Disorder

E. Rüther, G. Hajak, D. Wedekind, 1997, Pharmacopsychiatry.

Blood dyscrasias induced by psychotropic drugs.

H. Möller, E. Rüther, W. Ludwig, 2004, Pharmacopsychiatry.

Plasma homocysteine is a predictor of alcohol withdrawal seizures

E. Rüther, J. Kornhuber, S. Bleich, 2000, Neuroreport.

Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.

Dan J Stein, D. Baldwin, O. Dolberg, 2006, The Journal of clinical psychiatry.

Sertraline versus paroxetine in the treatment of panic disorder: A multinational randomized double-blind 15 week study

K. Behnke, G. Hendriks, B. Bandelow, 2002, European Neuropsychopharmacology.

Panic disorder — acceptance of the diagnostic entity and treatment modalities preferred by German health professionals

E. Rüther, G. Hajak, B. Bandelow, 1996, European Psychiatry.

How to grade categories of evidence

H. Möller, S. Kasper, J. Zohar, 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Hans-Jürgen Möller, Siegfried Kasper, Eric Hollander, 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

J. A. Boer, D. Nutt, J. Davidson, 2005, Journal of psychopharmacology.

A neurobiological framework of separation anxiety and related phenotypes

K. Domschke, D. Baldwin, B. Bandelow, 2020, European Neuropsychopharmacology.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

Dan J Stein, H. Möller, E. Hollander, 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice

H. Möller, E. Seifritz, H. Volz, 2016, European Archives of Psychiatry and Clinical Neuroscience.

Differenzierung und diagnostische Bedeutung der Immunglobulinklassen humoraler Antikörper gegen Zellwandantigene der Sproßzellen‐und Myzelphase von Candida albicans Differentiation and diagnostic significance of immunoglobulin classes of antibodies against cell wall antigens of yeast and mycelial ph

B. Bandelow, R. Thomssen, R. Ansorg, 1977 .

The use of parametric vs. nonparametric tests in the statistical evaluation of rating scales.

U. Munzel, B. Bandelow, B Bandelow, 1998, Pharmacopsychiatry.

Borderline personality disorder: a dysregulation of the endogenous opioid system?

P. Falkai, C. Schmahl, D. Wedekind, 2010, Psychological review.

[Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology].

S. Doering, D. Wedekind, B. Bandelow, 2001, Zeitschrift fur Psychosomatische Medizin und Psychotherapie.

Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

D. Wedekind, B. Bandelow, T. León, 2007, Expert review of neurotherapeutics.

[Etiology of initially unexplained confusion of excitability in deadly nightshade poisoning with suicidal intent. Symptoms, differential diagnosis, toxicology and physostigmine therapy of anticholinergic syndrome].

B. Bandelow, C. Binder, J. Chemnitius, 2000, Deutsche medizinische Wochenschrift.

Neuropeptide S receptor gene — converging evidence for a role in panic disorder

A. Gloster, G. Alpers, W. Maier, 2011, Molecular Psychiatry.

Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder

W. Maier, F. Holsboer, P. Unschuld, 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Chromosome 4q31‐34 panic disorder risk locus: Association of neuropeptide Y Y5 receptor variants

W. Maier, V. Arolt, K. Domschke, 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Embitterment syndrome: Options for psychopharmacological management

B. Bandelow, 2011 .

New Antidepressants in Comparison with Classical Tricyclics1

K. Junghanns, A. Broocks, A. Thiel, 2002 .

Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care

H. Möller, E. Hollander, S. Kasper, 2012, International journal of psychiatry in clinical practice.

TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies

S. Cichon, M. Rietschel, M. Nöthen, 2011, Molecular Psychiatry.

Borderline personality disorder - a dysregulation of the endogenous opioid system?

P. Falkai, C. Schmahl, D. Wedekind, 2011, European Psychiatry.

The quantification inventory for somatoform syndromes (QUISS): a novel instrument for the assessment of severity

E. Rüther, D. Wedekind, B. Bandelow, 2007, European Archives of Psychiatry and Clinical Neuroscience.

Association of polymorphisms in the angiotensin-converting enzyme gene with syndromal panic attacks

F. Holsboer, P. Unschuld, B. Müller-Myhsok, 2008, Molecular Psychiatry.

Gender Differences in Associations of Glutamate Decarboxylase 1 Gene (GAD1) Variants with Panic Disorder

G. Alpers, W. Maier, A. Hamm, 2012, PloS one.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD

Dan J Stein, D. Rujescu, E. Hollander, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Efficacy of treatments for anxiety disorders: a meta-analysis

D. Wedekind, B. Bandelow, C. Röver, 2015, International clinical psychopharmacology.

DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive–compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addic

H. Möller, W. Maier, H. Hampel, 2015, European Archives of Psychiatry and Clinical Neuroscience.

Depressive syndromes in schizophrenic patients after discharge from hospital

W. Gaebel, F. Reischies, B. Bandelow, 1990, European Archives of Psychiatry and Clinical Neuroscience.

WFSBP guidelines on how to grade treatment evidence for clinical guideline development

H. Möller, P. Falkai, S. Kasper, 2019, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

Dan J Stein, E. Hollander, D. Nutt, 2003, CNS Spectrums.

Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with depressive disorder and healthy controls

D. Wedekind, B. Bandelow, H. Peter, 2013, International journal of psychiatry in clinical practice.

Treatment of Obsessive-Compulsive Disorder

D. Stein, D. Baldwin, J. Ipser, 2007, CNS Spectrums.

Grey matter structural differences in alcohol-dependent individuals with and without comorbid depression/anxiety—an MRI study

Dan J Stein, D. Wedekind, A. Uhlmann, 2019, European Archives of Psychiatry and Clinical Neuroscience.

Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders

E. Rüther, D. Wedekind, B. Bandelow, 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Application of a new statistical approach to evaluate a clinical trial with panic disorder patients

E. Rüther, G. Hajak, A. Broocks, 1999, European Archives of Psychiatry and Clinical Neuroscience.

The use of the Panic and Agoraphobia Scale in a clinical trial

Göran Hajak, E. Rüther, G. Hajak, 1998, Psychiatry Research.

Panic Disorder and Agoraphobia

K. Domschke, V. Starcevic, D. Baldwin, 2007 .

Expressed emotion in the partners of a non-clinical adult sample: a comparison with relatives of patients with schizophrenia and depression

B. Dahme, M. Rufer, B. Bandelow, 2008 .

Manifesto for a European Anxiety Disorders Research Network

J. Vázquez-Barquero, A. Metspalu, N. Fineberg, 2010, European Neuropsychopharmacology.

Attachment style, anxiety coping, and personality-styles in withdrawn alcohol addicted inpatients

D. Wedekind, B. Bandelow, K. Engel, 2013, Substance Abuse Treatment, Prevention, and Policy.

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8‐week placebo‐controlled studies

Dan J Stein, B. Bandelow, H. Eriksson, 2011, Human psychopharmacology.

Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism

J. Kornhuber, S. Bleich, W. Sperling, 2003, Neuroscience Letters.

Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice

J. Wiltfang, D. Wedekind, B. Bandelow, 2019, BMC Psychiatry.

Functional MRI activation in response to panic-specific, non-panic aversive, and neutral pictures in patients with panic disorder and healthy controls

P. Dechent, O. Gruber, I. Zerr, 2016, European Archives of Psychiatry and Clinical Neuroscience.

The German guidelines for the treatment of anxiety disorders

M. Beutel, B. Bandelow, S. Rudolf, 2015, European Archives of Psychiatry and Clinical Neuroscience.

The diagnosis and treatment of generalized anxiety disorder.

H. Möller, S. Kasper, H. Wittchen, 2013, Deutsches Arzteblatt international.

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis

A. Young, A. Cleare, B. Carter, 2018, British Journal of Psychiatry.

How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database

Dan J Stein, D. Baldwin, O. Dolberg, 2009, Human psychopharmacology.

WCA Recommendations for the Long-Term Treatment of Social Phobia

Dan J Stein, E. Hollander, D. Nutt, 2003, CNS Spectrums.

Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline

M. Bauer, E. Vieta, B. Bandelow, 2014, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach

B. Bandelow, 2006, CNS Spectrums.

Current and Novel Psychopharmacological Drugs for Anxiety Disorders.

B. Bandelow, 2020, Advances in experimental medicine and biology.

DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 1: general aspects and paradigmatic discussion of depressive disorders

H. Möller, W. Maier, H. Hampel, 2015, European Archives of Psychiatry and Clinical Neuroscience.

“As Needed” Pharmacotherapy Combined with Stimulus Control Treatment in Chronic Insomnia—Assessment of a Novel Intervention Strategy in a Primary Care Setting

G. Hajak, B. Bandelow, J. Zulley, 2002, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Trends in der Angsttherapie

B. Bandelow, D. Wedekind, 2005 .

WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder

E. Hollander, D. Stein, D. Nutt, 2003, CNS Spectrums.

Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies

D. Wedekind, B. Bandelow, M. Belz, 2018, The British Journal of Psychiatry.

Clinically relevant drug interactions in anxiety disorders

D. Baldwin, B. Bandelow, E. Spina, 2012, Human psychopharmacology.

Non-pharmacological treatment

K. Domschke, D. Baldwin, B. Bandelow, 2013 .

Treatment-Resistant Panic Disorder

E. Rüther, B. Bandelow, 2004, CNS Spectrums.

Rebound insomnia after hypnotic withdrawal in insomniac outpatients

E. Rüther, G. Hajak, A. Broocks, 1998, European Archives of Psychiatry and Clinical Neuroscience.

[The impact of the central serotonin system on alcoholism and therapeutic consequences].

B. Bandelow, M. Krausz, H. Peter, 1998, Fortschritte der Neurologie Psychiatrie.

5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo

E. Rüther, D. Wedekind, A. Broocks, 2003, European Neuropsychopharmacology.

Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects

A. Broocks, B. Bandelow, C. Gleiter, 2001, Psychopharmacology.

Decreased Neuroendocrine Responses to Meta-Chlorophenylpiperazine (m-CPP) but Normal Responses to Ipsapirone in Marathon Runners

E. Rüther, G. Hajak, A. Broocks, 1999, Neuropsychopharmacology.

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis – CORRIGENDUM

A. Young, A. Cleare, B. Carter, 2018, The British Journal of Psychiatry.

Myocarditis associated with clozapine treatment.

E. Rüther, S. Bleich, B. Bandelow, 2000, The Australian and New Zealand journal of psychiatry.

Myocarditis under therapy with clozapine

E. Rüther, B. Bandelow, D. Degner, 1995, Schizophrenia Research.

RGS2 genetic variation: Association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety

A. Gloster, G. Alpers, A. Hamm, 2015, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia

E. Rüther, G. Hajak, B. Bandelow, 1995, Journal of pineal research.

WCA Recommendations for the Long-Term Treatment of Panic Disorder

E. Hollander, D. Nutt, M. Pollack, 2003, CNS Spectrums.

14-39 Salivary cortisol in panic disorder

E. Rüther, D. Wedekind, A. Broocks, 1997, Biological Psychiatry.

Separation Anxiety and Actual Separation Experiences during Childhood in Patients with Panic Disorder

E. Rüther, S. Bleich, G. Hajak, 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Posttraumatic stress disorder (PTSD) in the German Armed Forces: a retrospective study in inpatients of a German army hospital

P. Falkai, D. Wedekind, B. Bandelow, 2012, European Archives of Psychiatry and Clinical Neuroscience.

Escitalopram in the treatment of anxiety symptoms associated with depression

O. Dolberg, B. Bandelow, H. Andersen, 2007, Depression and anxiety.

Neuroimaging in anxiety disorders

Oliver Gruber, O. Gruber, D. Wedekind, 2008, Journal of Neural Transmission.

Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison.

K. Behnke, C. Clary, G. Hendriks, 2004, The Journal of clinical psychiatry.

Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality.

C. Freitag, W. Maier, F. Holsboer, 2010, Journal of psychiatric research.

Parallel increase of heterochromatic increment threshold and postadaptation thresholds in Parkinson's disease and in neuroleptic treatment

W. Paulus, B. Bandelow, B. Haug, 1997, Vision Research.

[Evidence-based medicine in therapy of anxiety disorders].

D. Wedekind, B. Bandelow, K. Engel, 2009, MMW Fortschritte der Medizin.

Intermittent Medication, Coping and Psychotherapy Interactions in Relapse Prevention and Course Modification

B. Bandelow, W. Gaebel, F. Müller-Spahn, 1992, British Journal of Psychiatry.

Network analyses to rank pharmacological treatments for generalised anxiety disorder

D. Wedekind, B. Bandelow, 2019, The Lancet.

Diurnal variation of cortisol in panic disorder

E. Rüther, G. Hajak, D. Wedekind, 2000, Psychiatry Research.

Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale

B. Bandelow, B Bandelow, 1995, International clinical psychopharmacology.

Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder.

E. Rüther, A. Broocks, B. Bandelow, 1998, The American journal of psychiatry.

Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion.

P. Falkai, D. Wedekind, B. Bandelow, 2010, Journal of psychiatric research.

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity

C. Allgulander, B. Bandelow, D. Wajsbrot, 2019, International clinical psychopharmacology.

[New antidepressive drugs in comparison with classical tricyclics. Mechanism of action and clinical evaluation].

K. Junghanns, A. Broocks, A. Thiel, 2000, Fortschritte der Neurologie Psychiatrie.

Depressive syndromes in schizophrenic patients under neuroleptic therapy

W. Gaebel, B. Bandelow, U. Frick, 2005, European Archives of Psychiatry and Clinical Neuroscience.

The relationship of separation anxiety with the age of onset of panic disorder.

K. Domschke, D. Baldwin, B. Bandelow, 2023, Early intervention in psychiatry.

Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems

E. Rüther, G. Hajak, B. Bandelow, 1995, International clinical psychopharmacology.

Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.

M. Trivedi, K. Demyttenaere, B. Bandelow, 2013, The international journal of neuropsychopharmacology.

[Value of sports in treatment of psychiatric illness].

E. Rüther, G. Hajak, A. Broocks, 1997, PPmP. Psychotherapie, Psychosomatik, medizinische Psychologie.

Selective Serotonin Reuptake Inhibitors, Reversible Inhibitors of Monoamine Oxidase‐A, and Buspirone

D. Wedekind, B. Bandelow, Markus Reitt, 2012 .

Sertraline and exposure therapy in social phobia

B. Bandelow, 2004, British Journal of Psychiatry.

Separation Anxiety and Measures of Suicide Risk Among Patients With Mood and Anxiety Disorders.

K. Domschke, C. Martini, D. Baldwin, 2021, Journal of Clinical Psychiatry.

Clozapine-associated elevation of plasma cholinesterase

E. Rüther, J. Wiltfang, S. Bleich, 2001, European Archives of Psychiatry and Clinical Neuroscience.

A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder

D. Wedekind, A. Broocks, B. Bandelow, 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Efficacy of treatments for anxiety disorders: a meta-analysis

D. Wedekind, B. Bandelow, C. Röver, 2015, International clinical psychopharmacology.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

H. Möller, E. Hollander, D. Stein, 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

J. A. Boer, D. Nutt, J. Davidson, 2005, Journal of psychopharmacology.

Depression (major depression)

B. Bandelow, Borwin Bandelow, U. Trenckmann, 1999 .

Clinically relevant drug interactions in anxiety disorders

D. Baldwin, B. Bandelow, E. Spina, 2012, Human psychopharmacology.

The panic and agoraphobia scale: results of validation processes

E. Rüther, G. Hajak, B. Bandelow, 1994, European Neuropsychopharmacology.

Blood Dyscrasias Induced by Psychotropic Drugs

H. Möller, E. Rüther, H. Hippius, 2004, Pharmacopsychiatry.

Comparison of the DSM–5 and ICD–10: panic and other anxiety disorders

B. Bandelow, 2017, CNS Spectrums.